BeyondSpring (NASDAQ:BYSI) Trading Down 2% - What's Next?

Key Points

• BeyondSpring Inc. (NASDAQ:BYSI) experienced a 2% decline in mid-day trading, dropping to a price as low as $1.96 before last trading at $2.01.
• The company's quarterly earnings report indicated an earnings per share of ($0.06) for the previous quarter, reflecting ongoing challenges in profitability.
• Geode Capital Management LLC significantly increased its stake in BeyondSpring by 951.4%, owning 256,212 shares after a substantial purchase, which makes up about 0.64% of the company.

BeyondSpring Inc. (NASDAQ:BYSI - Get Free Report) dropped 2% during mid-day trading on Tuesday . The stock traded as low as $1.96 and last traded at $2.01. Approximately 10,375 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 26,565 shares. The stock had previously closed at $2.05.

BeyondSpring Trading Down 2.0%

The company has a 50-day simple moving average of $2.30 and a two-hundred day simple moving average of $1.85.

BeyondSpring (NASDAQ:BYSI - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.06) earnings per share for the quarter.

Institutional Trading of BeyondSpring

A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC lifted its stake in BeyondSpring Inc. (NASDAQ:BYSI - Free Report) by 951.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 256,212 shares of the company's stock after purchasing an additional 231,844 shares during the quarter. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 40.29% of the company's stock.

About BeyondSpring

BeyondSpring Inc, a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.